S0622, Dasatinib in Treating Patients With Stage IV Breast Cancer That Has Spread to the Bone

Completed · Phase 2

Conditions studied: Breast Cancer, Metastatic Cancer

In brief

RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying two different schedules of dasatinib to compare how well they work in treating patients with stage IV breast cancer that has spread to the bone.

Key facts

Study ID
NCT00410813
Run by
SWOG Cancer Research Network
People needed
85
Starts
2007-03-01
Expected to finish
2014-01-01
Last updated by the study team
2017-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.